3-甲基吡啶-2-三氟甲磺酸酯 | 154447-02-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机磺酸及其衍生物
• 中文名称: 3-甲基吡啶-2-三氟甲磺酸酯
• 英文名称: 3-methylpyridin-2-yl trifluoromethanesulfonate
• 英文别名: (3-methylpyridin-2-yl) trifluoromethanesulfonate
• CAS: 154447-02-6
• 化学式: C₇H₆F₃NO₃S
• 分子量: 241.191
• InChiKey: KBHZMXPMBNDXPZ-UHFFFAOYSA-N

物化性质

• 沸点：
  281.1±40.0 °C(Predicted)
• 密度：
  1.504±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  64.6
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  3-甲基吡啶-2-三氟甲磺酸酯 在 盐酸 、 sodium iodide 、 sodium hydroxide 作用下， 以 乙醚 、 甲苯 、 水 为溶剂， 以7.63 g的产率得到2-碘-3-甲基吡啶
  参考文献：
  名称：

  羟基吡啶的一锅法碘化

  摘要：

  描述了羟基吡啶和羟基喹啉的一锅高产率的碘化。碘化反应在温和的条件下进行，不需要色谱纯化就可以高收率获得产物。另外，碘化作用在2-和4-羟基吡啶和-羟基喹啉上。

  DOI：

  10.1021/jo900726f
• 作为产物：
  描述：

  三氟甲磺酸酐 、 2-羟基-3-甲基吡啶 在 吡啶 作用下， 以 甲苯 为溶剂， 反应 2.0h， 生成 3-甲基吡啶-2-三氟甲磺酸酯
  参考文献：
  名称：

  羟基吡啶的一锅法碘化

  摘要：

  描述了羟基吡啶和羟基喹啉的一锅高产率的碘化。碘化反应在温和的条件下进行，不需要色谱纯化就可以高收率获得产物。另外，碘化作用在2-和4-羟基吡啶和-羟基喹啉上。

  DOI：

  10.1021/jo900726f

文献信息

• A General, Multimetallic Cross-Ullmann Biheteroaryl Synthesis from Heteroaryl Halides and Heteroaryl Triflates
  作者：Kai Kang、Nathan L. Loud、Tarah A. DiBenedetto、Daniel J. Weix

  DOI：10.1021/jacs.1c10907

  日期：2021.12.29

  medicine and materials science, the synthesis of biheteroaryls by cross-coupling remains challenging. We describe here a new, general approach to biheteroaryls: the Ni- and Pd-catalyzed multimetallic cross-Ullmann coupling of heteroaryl halides with triflates. An array of 5-membered, 6-membered, and fused heteroaryl bromides and chlorides, as well as aryl triflates derived from heterocyclic phenols,

  尽管它们对医学和材料科学很重要，但通过交叉偶联合成双杂芳基仍然具有挑战性。我们在这里描述了一种新的、通用的双杂芳基方法：杂芳基卤化物与三氟甲磺酸酯的 Ni 和 Pd 催化的多金属交叉 Ullmann 偶联。一系列 5 元、6 元和稠合杂芳基溴化物和氯化物，以及衍生自杂环酚的芳基三氟甲磺酸酯，被证明是该反应中可行的底物（62 个示例，平均产率为 63 ± 17%）。这种方法对双杂芳基的普遍性在 10 μmol 规模的 96 孔板格式中得到进一步证明。一组 96 种可能的产品在一组条件下提供了 >90% 的命中率。此外，可以使用配体、添加剂和还原剂的单个“工具箱板”快速优化低产率组合。
• Chromane, isochromane and dihydroisobenzofuran derivatives as mGluR2-negative allosteric modulators, compositions, and their use
  申请人：Merck Sharp & Dohme Corp.

  公开号：US10806724B2

  公开（公告）日：2020-10-20

  The present invention provides certain substituted chromane, isochromane, and dihydroisobenzofuran compounds of formula (I): or a pharmaceutically acceptable salt thereof, wherein ring A is a moiety selected from: and ring B, n, R1, R2, R2A, R3, and R3A are as defined herein. The compounds of the invention are useful as mGluR2 inhibitors, or mGluR2 negative allosteric modulators (NAMs), and may be useful in methods of treating a patient for diseases or disorders in which the mGluR2-NAM receptor is involved, such as Alzheimer's disease, cognitive impairment, mild cognitive impairment, schizophrenia and other mood disorders, pain disorders and sleep disorders, by administering to the patient a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof. The invention is also directed to pharmaceutical compositions comprising a compound of the invention, or a pharmaceutically acceptable salt thereof, (optionally in combination with one or more additional active ingredients), and a pharmaceutically acceptable carrier, and the use of the compounds and pharmaceutical compositions of the invention in the treatment of such diseases.

  本发明提供了某些取代的式 (I) 的铬烷、异铬烷和二氢异苯并呋喃化合物： 或其药学上可接受的盐，其中环 A 是选自以下的分子 和环 B、n、R1、R2、R2A、R3 和 R3A 如本文所定义。本发明的化合物可用作 mGluR2 抑制剂或 mGluR2 负性异位调节剂 (NAM)，并可用于通过向患者施用治疗有效量的本发明化合物或其药学上可接受的盐，来治疗患者涉及 mGluR2-NAM 受体的疾病或紊乱，如阿尔茨海默病、认知障碍、轻度认知障碍、精神分裂症和其他情绪紊乱、疼痛紊乱和睡眠紊乱。本发明还涉及包含本发明化合物或其药学上可接受的盐的药物组合物（可选择与一种或多种其它活性成分组合）和药学上可接受的载体，以及本发明化合物和药物组合物在治疗此类疾病中的用途。
• Practical Ni-Catalyzed Cross-Coupling of Unsaturated Zinc Pivalates with Unsaturated Nonaflates and Triflates
  作者：Maximilian S. Hofmayer、Ferdinand H. Lutter、Lucie Grokenberger、Jeffrey M. Hammann、Paul Knochel

  DOI：10.1021/acs.orglett.8b03417

  日期：2019.1.4

  A practical nickel-catalyzed cross-coupling of (hetero)aryl or alkynylzinc pivalates with various unsaturated nonaflates or triflates is described. Organozinc pivalates allow these cross-couplings to take place with high yields and a low catalyst loading (0.5 mol %). Couplings with (E)- and (Z)-alkenyl triflates proceed with retention of configuration.
• CHROMANE, ISOCHROMANE AND DIHYDROISOBENZOFURAN DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20190247374A1

  公开（公告）日：2019-08-15

  The present invention provides certain substituted chromane, isochromane, and dihydroisobenzofuran compounds of formula (I): or a pharmaceutically acceptable salt thereof, wherein ring A is a moiety selected from: and ring B, n, R 1 , R 2 , R 2A , R 3 , and R 3A are as defined herein. The compounds of the invention are useful as mGluR2 inhibitors, or mGluR2 negative allosteric modulators (NAMs), and may be useful in methods of treating a patient for diseases or disorders in which the mGluR2-NAM receptor is involved, such as Alzheimer's disease, cognitive impairment, mild congnitive impairment, schizophrenia and other mood disorders, pain disorders and sleep disorders, by administering to the patient a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof. The invention is also directed to pharmaceutical compositions comprising a compound of the invention, or a pharmaceutically acceptable salt thereof, (optionally in combination with one or more additional active ingredients), and a pharmaceutically acceptable carrier, and the use of the compounds and pharmaceutical compositions of the invention in the treatment of such diseases.